Clear, independent accounting judgement where deal structure, timing, and interpretation materially affect value.
I advise pharma, biotech, and med-tech leaders on complex IFRS questions before accounting positions harden, negotiations close, or audit scrutiny begins.
The highest-value advisory work happens early, while deal terms, commercial expectations, and accounting positions can still be shaped deliberately.
Identify accounting consequences while licensing, collaboration, or co-development terms are still negotiable.
Prepare clear, defensible positions on revenue recognition, variable consideration, milestones, and performance obligations.
Translate complex IFRS judgement into commercially intelligible analysis for decision-makers.
My work sits at the intersection of IFRS, transaction structure, and business judgement.
Analysis of rights, obligations, control, exclusivity, milestones, and the accounting implications embedded in deal terms.
Judgement on licences versus services, performance obligations, timing of recognition, and variable consideration constraints.
Pre-deal and post-deal analysis where accounting treatment may influence valuation, negotiation, or reported performance.
Position papers, challenge analysis, and clear rationale that can withstand technical review and external scrutiny.
When the accounting conclusion needs to be technically sound, commercially aware, and explainable to audit committees, boards, and investors.
When transaction terms may create accounting consequences that affect negotiation, valuation, or future reporting.
When licensing and collaboration arrangements sit close to valuation, fundraising, and investor confidence.
When independent technical clarity is needed on complex or contested financial reporting positions.
I start with the economics of the arrangement, not only the accounting question as presented.
I isolate the areas where structure, wording, timing, or estimation could drive a different accounting outcome.
I provide clear reasoning, challenge points, and documentation that supports decision-making and audit readiness.
The output is designed for action: board discussion, negotiation, audit response, investor explanation, or internal alignment.
Engage before deal terms are locked, positions are documented, or audit scrutiny begins. That is where the value sits.